{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:31:27Z","timestamp":1770679887103,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lungcan.2025.108630","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T11:52:27Z","timestamp":1750420347000},"page":"108630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase \u2161 study"],"prefix":"10.1016","volume":"205","author":[{"given":"Minna","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiafeng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaicheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9178-5493","authenticated-orcid":false,"given":"Bing","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.lungcan.2025.108630_b0005","first-page":"vi99","article-title":"Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fr\u00fch","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2025.108630_b0010","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.6004\/jnccn.2018.0079","article-title":"NCCN guidelines insights: small cell lung cancer \u2013 clinical practice guidelines in oncology, version 2.2018","volume":"16","author":"Kalemkerian","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108630_b0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMoa071780","article-title":"Prophylactic cranial irradiation in extensive small-cell lung cancer","volume":"357","author":"Slotman","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108630_b0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer: first-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108630_b0025","unstructured":"NCCN clinical practice guidelines in oncology. Small cell lung cancer V2, 21 November, 2023."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108630_b0030","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2025.108630_b0035","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","article-title":"Randomized phase III:trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer","volume":"32","author":"Pawel","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108630_b0040","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-019-0736-3","article-title":"Emerging therapies for small cell lung cancer","volume":"12","author":"Yang","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108630_b0045","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11864-018-0568-3","article-title":"Targeted therapy and immune therapy for small cell lung cancer","volume":"19","author":"Gadgeel","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108630_b0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-019-0540-1","article-title":"Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC)","volume":"7","author":"Carvajal-Hausdorf","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2025.108630_b0055","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108630_b0060","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41416-021-01356-3","article-title":"Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled phase 2 study","volume":"125","author":"Cheng","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108630_b0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000486622","article-title":"A phase II study of irinotecan for patients with previously treated small-cell lung cancer","volume":"94","author":"Kondo","year":"2018","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108630_b0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/curroncol28010036","article-title":"Real world analysis of small cell lung cancer patients: prognostic factors and treatment outcomes","volume":"28","author":"Waterhouse","year":"2021","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108630_b0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ccell.2021.03.003","article-title":"A rational targeted therapy for platinum-resistant small-cell lung cancer","volume":"39","author":"Drapkin","year":"2021","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108630_b0080","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108630_b0085","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/JTO.0b013e31824c7f4b","article-title":"A systematic analysis of efficacy of second line chemotherapy in sensitive and refractory small cell lung cancer","volume":"7","author":"Owonikoko","year":"2012","journal-title":"Thorac Oncol."},{"key":"10.1016\/j.lungcan.2025.108630_b0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2022.03.003","article-title":"DISTINCT study investigators, Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer","volume":"166","author":"Edelman","year":"2022","journal-title":"Lung Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2025.108630_b0095","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108630_b0100","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1200\/JCO.1997.15.5.2090","article-title":"Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease","volume":"15","author":"Ardizzoni","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2025.108630_b0105","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.annonc.2021.01.071","article-title":"Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331","volume":"32","author":"Spigel","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108630_b0110","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jtho.2019.12.109","article-title":"Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies","volume":"15","author":"Chung","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108630_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102543","article-title":"Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial","volume":"70","author":"Ma","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lungcan.2025.108630_b0120","article-title":"Synergistic antitumor effects of anlotinib combined with oral 5-fluorouracil\/S-1 via inhibiting Src\/AKT signaling pathway in small-cell lung cancer","volume":"16","author":"Xia","year":"2022","journal-title":"Anal. Cell. Pathol. (Amst.)"},{"key":"10.1016\/j.lungcan.2025.108630_b0125","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2147\/CMAR.S364125","article-title":"The efficacy and safety of anlotinib in extensive-stage small cell lung cancer: a multicenter real-world study","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2025.108630_b0130","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.2147\/CMAR.S249678","article-title":"A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer","volume":"12","author":"Wang","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2025.108630_b0135","article-title":"Efficacy and safety of anlotinib in the treatment of small cell lung cancer: a real-world observation study","volume":"12","author":"Yuan","year":"2022","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2025.108630_b0140","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.3390\/cancers15225368","article-title":"Unlocking new horizons in small-cell lung cancer treatment: the onset of antibody-drug conjugates","volume":"15","author":"Belluomini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2025.108630_b0145","doi-asserted-by":"crossref","unstructured":"C.M. Rudin, M.J. Ahn, M. Johnson, C.L. Hann, N. Girard, M. Nishio, Y. Cheng, H. Hayashi, Y.J. Kim, A. Navarro, Y. Chen, T. Sakai, M. Qian, J. Godard, M. Tang, J. Singh, L. Paz-Ares, Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC):interim analysis of Ideate-lung01, 2024 WCLC OA04.03.","DOI":"10.1016\/j.jtho.2024.09.033"},{"issue":"3","key":"10.1016\/j.lungcan.2025.108630_b0150","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.7150\/ijbs.105973","article-title":"Advancement opportunities and endeavor of innovative targeted therapies for small cell lung cancer","volume":"21","author":"Ouyang","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108630_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1078-0432.CCR-24-2350","article-title":"Phase I\/II investigator-initiated study of olaparib and temozolomide in SCLC: final analysis and CNS outcomes","volume":"31","author":"Meador","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2025.108630_b0160","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jtho.2019.04.026","article-title":"Durvalumab in combination with olaparib in patients with relapsed SCLC: results from a phase II study","volume":"14","author":"Thomas","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108630_b0165","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/cam4.5217","article-title":"A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:51:14Z","timestamp":1752591074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225005227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":33,"alternative-id":["S0169500225005227"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108630","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase \u2161 study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108630"}}